(S)-Ranolazine | 114246-81-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-Ranolazine
• 英文别名: ranolazine；N-(2,6-dimethylphenyl)-2-[4-[(2S)-2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
• CAS: 114246-81-0
• 化学式: C₂₄H₃₃N₃O₄
• 分子量: 427.544
• InChiKey: XKLMZUWKNUAPSZ-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  74.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,6-二甲基氯代乙酰苯胺 在 Candida antartica lipase in the form of CLEA 、 sodium dodecyl-sulfate 、 potassium carbonate 作用下， 以 甲醇 、 水 、 甲苯 为溶剂， 反应 66.0h， 生成 (S)-Ranolazine
  参考文献：
  名称：

  脂酶介导的化学酶促合成化学方法合成（S）-雷诺嗪，作为一种抗心绞痛药物

  摘要：

  在基于计算机模拟的生物催化方法中，以对映纯形式合成药物和药物中间体是一种有机化学途径上的合理化方法。在这项研究中，基于酶配体的...

  DOI：

  10.1039/c6ra06879k

文献信息

• Characteristic and complementary chiral recognition ability of four recently developed immobilized chiral stationary phases based on amylose and cellulose phenyl carbamates and benzoates
  作者：Takafumi Onishi、Takunori Ueda、Kenichi Yoshida、Kosuke Uosaki、Hiroyuki Ando、Ryota Hamasaki、Atsushi Ohnishi

  DOI：10.1002/chir.23446

  日期：2022.7

  various immobilized chiral stationary phases (CSPs) have been developed. The immobilized CSPs have opened up possibilities not only maintaining the high chiral recognition abilities as well as corresponding coated ones but also affording high durability to various mobile phase. This report directed to investigate enantioseparation of recently launched four immobilized CSPs with cellulose and amylose

  迄今为止，已经开发了各种固定化手性固定相 (CSP)。固定化的 CSP 不仅为保持高手性识别能力和相应的涂层能力开辟了可能性，而且为各种流动相提供了高耐久性。本报告旨在研究在正相液相色谱条件下最近推出的四种具有纤维素和直链淀粉骨架的固定化 CSP 的对映体分离。将它们的手性识别能力与之前开发的六种固定化 CSP 进行了比较。特别是，我们专注于手性识别的互补性。其中，直链淀粉三（3-氯-5-甲基苯基氨基甲酸酯）CSP，即CHIRALPAK IG，对各种外消旋体显示出显着的手性识别能力。正如预期的那样，研究的固定化 CSP 对各种流动相具有显着的耐久性，而相应的涂层 CSP 由于不可逆的降解而无法运行。利用不受限制的溶剂相容性，一些外消旋体的手性分离选择性得到改善。
• Nanocellulose Derivative/Silica Hybrid Core-Shell Chiral Stationary Phase: Preparation and Enantioseparation Performance
  作者：Xiaoli Zhang、Litao Wang、Shuqing Dong、Xia Zhang、Qi Wu、Liang Zhao、Yanping Shi

  DOI：10.3390/molecules21050561

  日期：——

  Core-shell silica microspheres with a nanocellulose derivative in the hybrid shell were successfully prepared as a chiral stationary phase by a layer-by-layer self-assembly method. The hybrid shell assembled on the silica core was formed using a surfactant as template by the copolymerization reaction of tetraethyl orthosilicate and the nanocellulose derivative bearing triethoxysilyl and 3,5-dimethylphenyl groups. The resulting nanocellulose hybrid core-shell chiral packing materials (CPMs) were characterized and packed into columns, and their enantioseparation performance was evaluated by high performance liquid chromatography. The results showed that CPMs exhibited uniform surface morphology and core-shell structures. Various types of chiral compounds were efficiently separated under normal and reversed phase mode. Moreover, chloroform and tetrahydrofuran as mobile phase additives could obviously improve the resolution during the chiral separation processes. CPMs still have good chiral separation property when eluted with solvent systems with a high content of tetrahydrofuran and chloroform, which proved the high solvent resistance of this new material.

  通过逐层自组装方法，成功制备了在混合壳中具有纳米纤维素衍生物的核壳硅微球作为手性固定相。在硅核上组装的混合壳是通过表面活性剂作为模板，通过正硅酸四乙酯与带有三乙氧基硅烷基和3,5-二甲基苯基的纳米纤维素衍生物的共聚反应形成的。对所得的纳米纤维素混合核壳手性填料（CPMs）进行了表征并装入色谱柱，通过高效液相色谱法评估了其手性分离性能。结果表明，CPMs具有均匀的表面形貌和核壳结构。在正相和反相模式下，各种类型的手性化合物均被有效地分离。此外，作为流动相添加剂的氯仿和四氢呋喃可以明显提高手性分离过程中的分辨率。当用四氢呋喃和氯仿含量高的溶剂体系洗脱时，CPMs仍然具有良好的手性分离性能，这证明了这种新材料具有很高的耐溶剂性。
• Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0126449A1

  公开（公告）日：1984-11-28

  Novel compounds of the general formula and the pharmaceutically acceptable esters and acid addition salts thereof, wherein: R1, R2, R3, R4, and R5 are each independently hydrogen, lower alkyl, lower alkoxy, cyano, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl, N-optionally substituted alkylamido, except that when R1 is methyl, R4 is not methyl; or R2 and R3 together form -OCH2O-; R6, R7, R8, R9 and R10 are each independently hydrogen, lower acyl, aminocarbonyl-methyl, arylcyano, lower alkyl, lower alkoxy, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl, di-lower alkyl amino; or R6 and R7 together form -CH = CH-CH = CH-; R7 and R8 together form -OCH2O -; R11 and R12 are each independently hydrogen or lower alkyl; and W is oxygen or sulfur. These cardioselective compounds have calcium entry blockade properties and therefore are useful in therapy in the treatment of cardiovascular diseases, including arrhythmias, variant and exercise induced angina and myocardial infarction.

  通式为 及其药学上可接受的酯和酸加成盐，其中 R1、R2、R3、R4 和 R5 各自独立地为氢、低级烷基、低级烷氧基、氰基、三氟甲基、卤代、低级烷硫基、低级烷基亚磺酰基、低级烷基磺酰基、N-可选取代的烷基氨基，但当 R1 为甲基时，R4 不是甲基；或 R2 和 R3 共同形成 -OCH2O-； R6、R7、R8、R9 和 R10 各自独立地为氢、低级酰基、氨基羰基甲基、芳基氰基、低级烷基、低级烷氧基、三氟甲基、卤代、低级烷硫基、低级烷基亚磺酰基、低级烷基磺酰基、二低级烷基氨基；或 R6 和 R7 共同形成 -CH = CH-CH = CH-； R7 和 R8 共同形成 -OCH2O -； R11 和 R12 各自独立地为氢或低级烷基；以及 W 是氧或硫。 这些心脏选择性化合物具有钙离子进入阻断特性，因此可用于治疗心血管疾病，包括心律失常、变异型和运动诱发的心绞痛和心肌梗塞。
• Sustained release ranolazine formulations
  申请人：CV THERAPEUTICS, INC.

  公开号：EP1527779A1

  公开（公告）日：2005-05-04

  The present invention relates to the use of ranolazine for the preparation of a pharmaceutical composition for treating a human suffering from a cardiovascular disease, wherein the pharmaceutical composition maintains ranolazine plasma levels in the human of from about 550 to about 7500 ng base/ml for at least 24 hours. Furthermore, the present invention relates to a pharmaceutical composition comprising ranolazine, at least one pH dependent binder and at least one pH independent binder for treating a human suffering from a cardiovascular disease.

  本发明涉及使用雷诺拉嗪制备用于治疗心血管疾病患者的药物组合物，其中该药物组合物可在至少24小时内将人体内的雷诺拉嗪血浆水平维持在约550至约7500纳克碱/毫升。此外，本发明还涉及一种药物组合物，该药物组合物包含雷诺拉嗪、至少一种与pH值相关的粘合剂和至少一种与pH值无关的粘合剂，用于治疗心血管疾病患者。
• Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
  申请人：CV THERAPEUTICS, INC.

  公开号：EP2033633A2

  公开（公告）日：2009-03-11

  Disclosed is the use of partial inhibitors of fatty acid oxidation for the manufacture of a medicament for treating congestive heart failure. The compounds increase cardiac performance without affecting heart rate, blood pressure, or oxygen consumption.

  本发明公开了脂肪酸氧化部分抑制剂用于制造治疗充血性心力衰竭的药物。这些化合物可提高心脏性能，而不影响心率、血压或耗氧量。